Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Abemaciclib in Combination With Pembrolizumab in Patients With Metastatic or Recurrent Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03938337
Recruitment Status : Completed
First Posted : May 6, 2019
Last Update Posted : January 29, 2021
Sponsor:
Information provided by (Responsible Party):
Eddy Yang, University of Alabama at Birmingham

Brief Summary:
To assess the objective response rate of tumor lesions to abemaciclib in combination with pembrolizumab in patients with metastatic or recurrent squamous cell carcinoma of head and neck.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Drug: Cohort 1 Not Previously Treated Drug: Cohort 2 Treated Previously Phase 2

Detailed Description:
Immunotherapy has been recently approved for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. However, only a small percentage of patients experience long-term control, necessitating new therapeutic strategies. Recently, it was shown preclinically and in breast tumors that abemaciclib stimulates production of type III interferons and hence enhances tumor antigen presentation. Abemaciclib also suppressed the proliferation of regulatory T cells. These events promote cytotoxic T-cell-mediated clearance of tumor cells, which is further enhanced by the addition of immune checkpoint blockade. Based on these data, a phase II trial in patients with metastatic or recurrent head and neck cancer who are eligible for immunotherapy is proposed to investigate the combination of abemaciclib with pembrolizumab. Tumor & blood analysis for interferon gamma signature will be explored as possible biomarkers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Trial of Abemaciclib in Combination With Pembrolizumab in Patients With Metastatic or Recurrent Head and Neck Cancer
Actual Study Start Date : October 8, 2019
Actual Primary Completion Date : April 1, 2020
Actual Study Completion Date : April 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort 1 Not Previously Treated
Patients with metastatic or recurrent head and neck cancer who have not been treated previously with immunotherapy.
Drug: Cohort 1 Not Previously Treated
Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
Other Name: CDK4:CDK6

Experimental: Cohort 2 Treated Previously
Patients with metastatic or recurrent head and neck cancer who have been treated previously with immunotherapy.
Drug: Cohort 2 Treated Previously
Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
Other Name: CDK4:CDK6




Primary Outcome Measures :
  1. To assess the objective response rate of tumor lesions using scans [ Time Frame: Baseline ]
    Patients will be evaluated for their tumor response to treatment using RECIST criteria on their scans

  2. To assess the objective response rate of tumor lesions using scans [ Time Frame: Baseline to 5 months ]
    Patients will be evaluated for their tumor response to treatment using RECIST criteria on their scans

  3. To assess the objective response rate of tumor lesions using scans [ Time Frame: Baseline to 8 months ]
    Patients will be evaluated for their tumor response to treatment using RECIST criteria on their scans


Secondary Outcome Measures :
  1. Number of participants experiencing adverse events grade 3 or greater [ Time Frame: Baseline to 1 month ]
    Measure adverse events grade 3 or greater to evaluate safety and tolerability

  2. Number of participants experiencing adverse events grade 3 or greater [ Time Frame: Baseline to 6 months ]
    Measure adverse events grade 3 or greater to evaluate safety and tolerability

  3. Number of participants experiencing adverse events grade 3 or greater [ Time Frame: Baseline to 12 months ]
    Measure adverse events grade 3 or greater to evaluate safety and tolerability

  4. To assess progression free survival (PFS) [ Time Frame: baseline to 6 months ]
    Using scan results to assess whether tumor has progressed and the time;

  5. To assess progression free survival (PFS) [ Time Frame: baseline to 12 months ]
    Using scan results to assess whether tumor has progressed and the time;

  6. To assess overall survival [ Time Frame: baseline to 6 months ]
    time that the patient is experiencing survival

  7. To assess overall survival [ Time Frame: baseline to 12 months ]
    time that the patient is experiencing survival

  8. To assess the time to tumor response [ Time Frame: baseline to 6 months ]
    using scan results to assess the time it takes for the tumor to respond to treatment

  9. To assess the time to tumor response [ Time Frame: baseline to 12 months ]
    using scan results to assess the time it takes for the tumor to respond to treatment

  10. To assess the duration of response [ Time Frame: baseline to 6 months ]
    using scan results to measure the total amount of time that the tumor is responding to treatment

  11. To assess the duration of response [ Time Frame: baseline to 12 months ]
    using scan results to measure the total amount of time that the tumor is responding to treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed (core biopsy proven) metastatic or recurrent squamous cell carcinoma of head and neck
  • Adequate pulmonary and cardiac function
  • Available archived tissue of primary tumor or resected tumor specimen with adequate samples
  • Prior treatment with immune checkpoint inhibitor is not allowed in cohort 1 patients. Patients in cohort 2 should have failed or progressed on prior immune checkpoint inhibitor
  • Eastern Cooperative Oncology Group Performance Status(ECOG PS) = 0 or 1
  • Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse [CTCAE] Grade <= 1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at lease 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy)
  • Patients who received adjuvant radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization
  • The patient is able to swallow oral medications
  • Adequate hematologic and end-organ function
  • Absolute Neutrophil Count (ANC) >= 1500/mm3
  • Platelet count ≥ 100,000/mm3
  • Hemoglobin (Hb) ≥ 8g/dl (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion)
  • Creatinine (Cr) ≤ 1.5 x Upper Limit of Normal (ULN) or Creatinine Clearance (CrCl) ≥ 60 ml/min
  • Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert syndrome, who can have total Bilirubin < 2.0 x ULN and direct bilirubin within normal limits are permitted.)
  • Aspartate Aminotransferase (AST) and Alanine aminotransferase (ALT) and alkaline phosphatase ≤ ULN
  • Agreement to remain abstinent or use appropriate contraception, among women of childbearing potential
  • Willingness and ability to consent for self to participate in study
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

  • Autoimmune disease (Note: Vitiligo, type 1 diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, and conditions not expected to recur in the absence of an external trigger are permitted.)
  • Condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to study treatment (Note: Inhaled and topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.)
  • Preexisting medical condition(s) that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  • Immunosuppression, of any kind
  • Prior treatment with Cyclin-Dependent Kinase(CDK) 4/6 Inhibitor
  • Major surgical procedure or significant traumatic injury within 4 weeks prior to study treatment, and must have fully recovered from any such procedure
  • Personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
  • Angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack TIA), arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) within 6 months prior to study treatment
  • Known active viral or non-viral hepatitis or cirrhosis
  • Any active infection requiring systemic treatment, positive tests for Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA).
  • History of gastrointestinal perforation or fistula in the 6 months prior to study treatment, unless underlying risk has been resolved (e.g., through surgical resection or repair)
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
  • Pregnancy or breastfeeding - Female patients must be surgically sterile (i.e., ≥6 weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) or be postmenopausal, or must agree to use effective contraception during the study and for 4 months following last dose of treatment. All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to study treatment. Male patients must be surgically sterile or must agree to use effective contraception during the study and for 4 months following last dose of treatment.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03938337


Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
Layout table for investigator information
Principal Investigator: Eddy Yang, MD University of Alabama at Birmingham
Layout table for additonal information
Responsible Party: Eddy Yang, Primary Investigator, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT03938337    
Other Study ID Numbers: UAB 1891
First Posted: May 6, 2019    Key Record Dates
Last Update Posted: January 29, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: To Be Determined
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: As long as study record is posted on CT.gov
Access Criteria: To Be Determined

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Eddy Yang, University of Alabama at Birmingham:
immunotherapy
abemaciclib
pembrolizumab
Cyclin-Dependent Kinase (CDK): CDK4
Cyclin-Dependent Kinase (CDK): CDK6
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms